Case Report: Neurological immune-related adverse events with anti-PD-1 based immunotherapy in cervical cancer
-
By
-
Gaia Passarella
-
Sofia Vella
-
Erminia Ferrario
-
Nicoletta Provinciali
-
Diego Luigi Cortinovis
-
Stefania Canova
-
May 14, 2026
-
Clinical Scorecard: Report on Neurological Immune-Related Adverse Events Associated with Anti-PD-1 Immunotherapy in Cervical Cancer Patients
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Patients with recurrent or metastatic HPV-related cervical cancer |
| Care Setting | |
Key Highlights
- Add highlight: 'Monitoring for neurological irAEs is crucial due to their potential severity.'
Guideline-Based Recommendations
Diagnosis
Management
- Include references to KEYNOTE-826 and EMPOWER-Cervical 1 trial results.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Clarify the role of PD-L1 positivity in improving overall survival.
Clinical Best Practices
- Add: 'Consider genetic counseling for patients with HPV-related cervical cancer.'
Related Resources & Content
